X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Piramal Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs PIRAMAL ENTERPRISES - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA PIRAMAL ENTERPRISES SUN PHARMA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 25.6 36.7 69.9% View Chart
P/BV x 3.7 3.0 122.8% View Chart
Dividend Yield % 0.6 0.8 76.9%  

Financials

 SUN PHARMA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    SUN PHARMA
Mar-17
PIRAMAL ENTERPRISES
Mar-17
SUN PHARMA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs8422,095 40.2%   
Low Rs5721,025 55.8%   
Sales per share (Unadj.) Rs131.6492.8 26.7%  
Earnings per share (Unadj.) Rs32.772.6 45.1%  
Cash flow per share (Unadj.) Rs38.094.7 40.1%  
Dividends per share (Unadj.) Rs3.5021.00 16.7%  
Dividend yield (eoy) %0.51.3 36.8%  
Book value per share (Unadj.) Rs152.7862.5 17.7%  
Shares outstanding (eoy) m2,399.26172.56 1,390.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.43.2 169.7%   
Avg P/E ratio x21.621.5 100.6%  
P/CF ratio (eoy) x18.616.5 113.0%  
Price / Book Value ratio x4.61.8 256.0%  
Dividend payout %10.728.9 37.0%   
Avg Mkt Cap Rs m1,696,877269,194 630.4%   
No. of employees `00017.54.0 436.5%   
Total wages/salary Rs m49,02317,939 273.3%   
Avg. sales/employee Rs Th18,028.321,190.3 85.1%   
Avg. wages/employee Rs Th2,798.84,470.1 62.6%   
Avg. net profit/employee Rs Th4,479.53,120.0 143.6%   
INCOME DATA
Net Sales Rs m315,78485,037 371.4%  
Other income Rs m6,2322,338 266.6%   
Total revenues Rs m322,01687,374 368.5%   
Gross profit Rs m100,89334,991 288.3%  
Depreciation Rs m12,6483,817 331.3%   
Interest Rs m3,99820,310 19.7%   
Profit before tax Rs m90,47913,202 685.3%   
Minority Interest Rs m01,699 0.0%   
Prior Period Items Rs m990-   
Extraordinary Inc (Exp) Rs m0-100 0.0%   
Tax Rs m12,1162,281 531.1%   
Profit after tax Rs m78,46212,520 626.7%  
Gross profit margin %31.941.1 77.6%  
Effective tax rate %13.417.3 77.5%   
Net profit margin %24.814.7 168.8%  
BALANCE SHEET DATA
Current assets Rs m329,53787,590 376.2%   
Current liabilities Rs m178,870185,578 96.4%   
Net working cap to sales %47.7-115.2 -41.4%  
Current ratio x1.80.5 390.3%  
Inventory Days Days7931 254.5%  
Debtors Days Days8348 175.1%  
Net fixed assets Rs m204,766108,523 188.7%   
Share capital Rs m2,399345 695.2%   
"Free" reserves Rs m363,997148,481 245.1%   
Net worth Rs m366,397148,826 246.2%   
Long term debt Rs m14,361144,957 9.9%   
Total assets Rs m614,102482,394 127.3%  
Interest coverage x23.61.7 1,432.2%   
Debt to equity ratio x01.0 4.0%  
Sales to assets ratio x0.50.2 291.7%   
Return on assets %13.46.8 197.3%  
Return on equity %21.48.4 254.5%  
Return on capital %24.812.0 207.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m44,11815,001 294.1%   
Fx outflow Rs m24,4845,150 475.4%   
Net fx Rs m19,6349,851 199.3%   
CASH FLOW
From Operations Rs m70,822-100,393 -70.5%  
From Investments Rs m-42,216-24,202 174.4%  
From Financial Activity Rs m-22,854135,705 -16.8%  
Net Cashflow Rs m6,10711,110 55.0%  

Share Holding

Indian Promoters % 63.7 52.9 120.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 4.0 128.3%  
FIIs % 23.0 26.6 86.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 16.5 50.3%  
Shareholders   133,026 93,274 142.6%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   ASTRAZENECA PHARMA  DR. DATSONS LABS  ELDER PHARMA  GSK PHARMA  PANACEA BIOTECH  

Compare SUN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Marginally Down; Tata Steel Top Loser(09:30 am)

Asian stocks rose in morning trade on Monday, after the US's S&P 500 extended its winning streak on Friday to six days. Markets in the Greater China region remain closed for the Lunar New Year holiday.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Feb 19, 2018 10:15 AM

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - CIPLA COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS